Miralinc Pharma Inc
- Biotech or pharma, therapeutic R&D
Miralinc has breakthrough next generation ultra potent HDAC6 inhibitor drug candidates. Lead candidate MRL-A102 is in IND development for peripheral neuropathies (CIPN, CMT ) with pipeline candidates for CNS and other HDAC6i indications.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}